de Morgan Stanley Ligand Pharmaceuticals LGND Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 63.4 M | Comprar |
200,699
+33,470
| +20% | +USD 7.89 M | ﹤0.01% | 1998 |
|
|
2026
Q1 | USD 33.4 M | Vender |
167,229
-26,173
| -14% | -USD 5.18 M | ﹤0.01% | 2495 |
|
|
2025
Q4 | USD 36.6 M | Comprar |
193,402
+4,701
| +2% | +USD 903 k | ﹤0.01% | 2386 |
|
|
2025
Q3 | USD 33.4 M | Vender |
188,701
-13,708
| -7% | -USD 2.04 M | ﹤0.01% | 2387 |
|
|
2025
Q2 | USD 23 M | Vender |
202,409
-36,683
| -15% | -USD 3.92 M | ﹤0.01% | 2662 |
|
|
2025
Q1 | USD 25.1 M | Comprar |
239,092
+31,230
| +15% | +USD 3.53 M | ﹤0.01% | 2459 |
|
|
2024
Q4 | USD 22.3 M | Vender |
207,862
-29,151
| -12% | -USD 3.3 M | ﹤0.01% | 2644 |
|
|
2024
Q3 | USD 23.7 M | Comprar |
237,013
+42,675
| +22% | +USD 4.3 M | ﹤0.01% | 2632 |
|
|
2024
Q2 | USD 16.4 M | Vender |
194,338
-57,559
| -23% | -USD 4.58 M | ﹤0.01% | 2879 |
|
|
2024
Q1 | USD 18.4 M | Comprar |
251,897
+52,703
| +26% | +USD 3.89 M | ﹤0.01% | 2786 |
|
|
2023
Q4 | USD 14.2 M | Comprar |
199,194
+4,187
| +2% | +USD 247 k | ﹤0.01% | 3020 |
|
|
2023
Q3 | USD 11.7 M | Comprar |
195,007
+26,741
| +16% | +USD 1.76 M | ﹤0.01% | 2981 |
|
|
2023
Q2 | USD 12.1 M | Comprar |
168,266
+13,187
| +9% | +USD 989 k | ﹤0.01% | 2983 |
|
|
2023
Q1 | USD 11.4 M | Vender |
155,079
-29,491
| -16% | -USD 2.1 M | ﹤0.01% | 3028 |
|
|
2022
Q4 | USD 12.3 M | Vender |
184,570
-8,534
| -4% | -USD 555 k | ﹤0.01% | 2866 |
|
|
2022
Q3 | USD 10.4 M | Vender |
193,104
-44,478
| -19% | -USD 2.61 M | ﹤0.01% | 2940 |
|
|
2022
Q2 | USD 13.2 M | Comprar |
237,582
+9,045
| +4% | +USD 513 k | ﹤0.01% | 2756 |
|
|
2022
Q1 | USD 16 M | Comprar |
228,537
+103,610
| +83% | +USD 7.52 M | ﹤0.01% | 2362 |
|
|
2021
Q4 | USD 12 M | Vender |
124,927
-28,259
| -18% | -USD 2.61 M | ﹤0.01% | 2739 |
|
|
2021
Q3 | USD 13.3 M | Comprar |
153,186
+10,101
| +7% | +USD 781 k | ﹤0.01% | 2566 |
|
|
2021
Q2 | USD 11.7 M | Comprar |
143,085
+38,590
| +37% | +USD 3.21 M | ﹤0.01% | 2802 |
|
|
2021
Q1 | USD 9.9 M | Comprar |
104,495
+29,997
| +40% | +USD 2.84 M | ﹤0.01% | 2659 |
|
|
2020
Q4 | USD 4.62 M | Vender |
74,498
-87,913
| -54% | -USD 5.01 M | ﹤0.01% | 3340 |
|
|
2020
Q3 | USD 9.7 M | Comprar |
162,411
+77,691
| +92% | +USD 5.3 M | ﹤0.01% | 2061 |
|
|
2020
Q2 | USD 5.91 M | Comprar |
84,720
+54,513
| +180% | +USD 3.46 M | ﹤0.01% | 2500 |
|
|
2020
Q1 | USD 1.37 M | Vender |
30,207
-162,820
| -84% | -USD 9.23 M | ﹤0.01% | 3693 |
|
|
2019
Q4 | USD 12.6 M | Comprar |
193,027
+129,313
| +203% | +USD 8.64 M | ﹤0.01% | 2147 |
|
|
2019
Q3 | USD 3.96 M | Comprar |
63,714
+10,736
| +20% | +USD 674 k | ﹤0.01% | 3124 |
|
|
2019
Q2 | USD 3.77 M | Comprar |
52,978
+35,691
| +206% | +USD 2.63 M | ﹤0.01% | 3218 |
|
|
2019
Q1 | USD 1.36 M | Vender |
17,287
-183,801
| -91% | -USD 13.9 M | ﹤0.01% | 3896 |
|
|
2018
Q4 | USD 17 M | Comprar |
201,088
+7,300
| +4% | +USD 778 k | 0.01% | 1605 |
|
|
2018
Q3 | USD 33.2 M | Vender |
193,788
-18,880
| -9% | -USD 2.85 M | 0.01% | 1247 |
|
|
2018
Q2 | USD 27.5 M | Comprar |
212,668
+77,667
| +58% | +USD 8.67 M | 0.01% | 1345 |
|
|
2018
Q1 | USD 13.9 M | Vender |
135,001
-54,179
| -29% | -USD 5.36 M | ﹤0.01% | 2021 |
|
|
2017
Q4 | USD 16.2 M | Comprar |
189,180
+29,736
| +19% | +USD 2.58 M | ﹤0.01% | 1899 |
|
|
2017
Q3 | USD 13.5 M | Comprar |
159,444
+111,275
| +231% | +USD 8.81 M | ﹤0.01% | 1973 |
|
|
2017
Q2 | USD 3.65 M | Vender |
48,169
-10,116
| -17% | -USD 708 k | ﹤0.01% | 3216 |
|
|
2017
Q1 | USD 3.85 M | Vender |
58,285
-77,686
| -57% | -USD 5.11 M | ﹤0.01% | 3140 |
|
|
2016
Q4 | USD 8.62 M | Comprar |
135,971
+74,666
| +122% | +USD 4.71 M | ﹤0.01% | 2419 |
|
|
2016
Q3 | USD 3.9 M | Vender |
61,305
-147,587
| -71% | -USD 10.8 M | ﹤0.01% | 2914 |
|
|
2016
Q2 | USD 15.5 M | Comprar |
208,892
+1,717
| +0.8% | +USD 127 k | 0.01% | 1625 |
|
|
2016
Q1 | USD 13.8 M | Comprar |
207,175
+70,527
| +52% | +USD 4.29 M | 0.01% | 1607 |
|
|
2015
Q4 | USD 9.24 M | Comprar |
136,648
+108,551
| +386% | +USD 6.7 M | ﹤0.01% | 2059 |
|
|
2015
Q3 | USD 1.5 M | Vender |
28,097
-90,254
| -76% | -USD 5.48 M | ﹤0.01% | 3769 |
|
|
2015
Q2 | USD 7.45 M | Comprar |
118,351
+105,263
| +804% | +USD 5.74 M | ﹤0.01% | 2404 |
|
|
2015
Q1 | USD 630 k | Vender |
13,088
-5,029
| -28% | -USD 193 k | ﹤0.01% | 4490 |
|
|
2014
Q4 | USD 601 k | Vender |
18,117
-8,068
| -31% | -USD 262 k | ﹤0.01% | 4530 |
|
|
2014
Q3 | USD 767 k | Vender |
26,185
-7,855
| -23% | -USD 261 k | ﹤0.01% | 4267 |
|
|
2014
Q2 | USD 1.32 M | Vender |
34,040
-20,749
| -38% | -USD 842 k | ﹤0.01% | 3822 |
|
|
2014
Q1 | USD 2.3 M | Vender |
54,789
-30,050
| -35% | -USD 1.25 M | ﹤0.01% | 3299 |
|
|
2013
Q4 | USD 2.78 M | Comprar |
84,839
+18,949
| +29% | +USD 617 k | ﹤0.01% | 3119 |
|
|
2013
Q3 | USD 1.78 M | Vender |
65,890
-17,068
| -21% | -USD 480 k | ﹤0.01% | 3327 |
|
|
2013
Q2 | USD 1.94 M | Comprar |
+82,958
| Nuevas | +USD 1.49 M | ﹤0.01% | 3178 |
|
Otros fondos que tienen LGND en su cartera
Posición de Morgan Stanley en LGND: resumen de T2 2026
Morgan Stanley aumentó su participación en Ligand Pharmaceuticals (LGND) en 20% durante T2 2026, al comprar aproximadamente USD 7.89 M y elevar la posición a 200,699 acciones con un valor de USD 63.4 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #1998.
Morgan Stanley reportó por primera vez una posición en LGND en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 420 fondos que sigue Wall St. Rank mantienen una posición en LGND.
- Al cierre de T2 2026, Morgan Stanley tenía 200,699 acciones de Ligand Pharmaceuticals con un valor de USD 63.4 M.
- Morgan Stanley compró 33,470 acciones de Ligand Pharmaceuticals en T2 2026, por un monto estimado de USD 7.89 M.
- Ligand Pharmaceuticals representó ﹤0.01% de la cartera de Morgan Stanley en T2 2026 y fue su posición número 1998.
- Morgan Stanley reportó por primera vez una posición en Ligand Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 420 fondos que sigue Wall St. Rank tenían Ligand Pharmaceuticals en cartera.
Según el Informe 13F de Morgan Stanley correspondiente a T2 2026, presentado el 13 ago 2026.